Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. (2022)

First Author: Pollock KM

Attributed to: saRNA SARS-CoV-2 vaccine funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.eclinm.2021.101262

PubMed Identifier: 35043093

Publication URI: http://europepmc.org/abstract/MED/35043093

Type: Journal Article/Review

Volume: 44

Parent Publication: EClinicalMedicine

ISSN: 2589-5370